Download PDF
Synlett 2002(5): 0755-0758
DOI: 10.1055/s-2002-25336
LETTER
© Georg Thieme Verlag Stuttgart · New York

Synthesis of Enantiopure 1-Benzyl-2,3-disubstituted Piperazines from Enantiopure p-Toluenesulfinimines

Alma Viso*a, Roberto Fernández de la Pradilla*a, María L. López-Rodríguezb, Ana Garcíaa, Mariola Tortosaa
a Instituto de Química Orgánica, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain
b Departamento de Química Orgánica I, Facultad de Ciencias Químicas, Universidad Complutense, 28040 Madrid, Spain
Fax: +34(91)5644853; e-Mail: iqov379@iqog.csic.es; e-Mail: iqofp19@iqog.csic.es;
Further Information

Publication History

Received 7 February 2002
Publication Date:
07 February 2007 (online)

    Permissions and Reprints All articles of this category

Abstract

The treatment of enantiopure N-sulfinyl-N′-benzyldiaminoalcohols with diethyl oxalate and sodium methoxide followed by reduction with BH3 affords enantiopure 1-benzyl-2,3-disubstituted piperazines. A related sequence produces substituted monoketopiperazines in good yields.

Key words

piperazines - amino alcohols - sulfinimines - chiral auxiliaries - asymmetric synthesis

    References

  • 1 Dorsey BD. Levin RB. McDaniel SL. Vacca JP. Guare JP. Darke PL. Zugay JA. Emini EA. Schleif WA. Quintero JC. Lin JH. Chen I.-W. Holloway MK. Fitzgerald PMD. Axel MG. Ostovic D. Anderson PS. Huff JR. J. Med. Chem.  1994,  37:  3443 
    CrossrefPubMedGoogle Scholar
  • Some references on ET-743 and related compounds:
  • 2a Rinehart KL. Holt TG. Fregeau NL. Keifer PA. Wilson GR. Perun TJ. Sakai R. Thompson AG. Stroh JG. Shield LS. Seigler DS. Li LH. Martin DG. Grimmelikhuijzen CJP. Gäde G. J. Nat. Prod.  1990,  53:  771 
    CrossrefGoogle Scholar
  • 2b Myers AG. Plowright AT. J. Am. Chem. Soc.  2001,  123:  5114 
    CrossrefGoogle Scholar
  • 2c Scott JD. Williams RM. Angew. Chem. Int. Ed.  2001,  40:  1463 
    CrossrefGoogle Scholar
  • 3a López-Rodríguez ML. Ayala D. Benhamú B. Morcillo MJ. Viso A. Curr. Med. Chem.  2002,  9:  1867 
    Google Scholar
  • 3b Olivier B. Soudijn W. van Wijngaarden I. Prog. Drug Res.  1999,  52:  103 
    Google Scholar
  • 4a Kawasaki T. Enoki H. Matsumura K. Ohyama M. Inagawa M. Sakamoto M. Org. Lett.  2000,  2:  3027 
    CrossrefGoogle Scholar
  • 4b Miyake FY. Yakushijin K. Horne DA. Org. Lett.  2000,  2:  3185 
    CrossrefGoogle Scholar
  • 4c For other piperazines with significant biological actitvity, see: Bedürftig S. Weigl M. Wünsch B. Tetrahedron: Asymmetry  2001,  12:  1293 ; and references cited therein
    CrossrefGoogle Scholar
  • 4d Beugelmans R. Bigot A. Bois-Choussy M. Zhu J. J. Org. Chem.  1996,  61:  771 ; and references cited therein
    CrossrefGoogle Scholar
  • 5 Dinsmore CJ. Bogusky MJ. Culberson JC. Bergman JM. Homnick CF. Zartman CB. Mosser SD. Schaber MD. Robinson RG. Koblan KS. Huber HE. Graham SL. Hartman GD. Huff JR. Williams TM. J. Am. Chem. Soc.  2001,  123:  2107 
    CrossrefGoogle Scholar
  • 6a Rübsam F. Mazitschek R. Giannis A. Tetrahedron  2000,  56:  8481 
    CrossrefGoogle Scholar
  • 6b Nefzi A. Giulianotti MA. Houghten RA. Tetrahedron  2000,  56:  3319 
    CrossrefGoogle Scholar
  • 6c Bailey PD. Boa AN. Baker SR. Clayson J. Murray EJ. Rosair GM. Tetrahedron Lett.  1999,  40:  7557 
    CrossrefGoogle Scholar
  • For other biologically active ketopiperazines, see:
  • 7a Govek SP. Overman LE. J. Am. Chem. Soc.  2001,  123:  9468 
    CrossrefGoogle Scholar
  • 7b Overman LE. Paone DV. J. Am. Chem. Soc.  2001,  123:  9465 
    CrossrefGoogle Scholar
  • 7c Singh SB. Tomassini JE. J. Org. Chem.  2001,  66:  5504 
    CrossrefGoogle Scholar
  • 8a Iyer MS. Gigstad KM. Namdev ND. Lipton M. J. Am. Chem. Soc.  1996,  118:  4910 
    Google Scholar
  • 8b Niwa S. Soai K. J. Chem. Soc., Perkin Trans. 1  1991,  2717 
    Google Scholar
  • 8c Falorni M. Satta M. Conti S. Giacomelli G. Tetrahedron: Asymmetry  1993,  4:  2389 
    Google Scholar
  • 8d Itsuno S. Matsumoto T. Sato D. Inoue T. J. Org. Chem.  2000,  65:  5879 
    Google Scholar
  • 8e Eriksson J. Arvidsson PI. Davidsson . Chem.-Eur. J.  1999,  5:  2356 
    Google Scholar
  • 9a Nefzi A. Giulianotti MA. Houghten RA. Tetrahedron Lett.  1999,  40:  8539 
    CrossrefGoogle Scholar
  • 9b Santes V. Gómez E. Zárate V. Santillan R. Farfán N. Rojas-Lima S. Tetrahedron: Asymmetry  2001,  12:  241 
    CrossrefGoogle Scholar
  • 9c Wang T. Zhang Z. Meanwell NA. J. Org. Chem.  2000,  65:  4740 
    CrossrefGoogle Scholar
  • 9d Soukara S. Wünsch B. Synthesis  1999,  1739 
    CrossrefGoogle Scholar
  • 9e Abdel-Jalil RJ. Al-Qawasmeh RA. Al-Abed Y. Voelter W. Tetrahedron Lett.  1998,  39:  7703 
    CrossrefGoogle Scholar
  • 9f Mickelson JW. Belonga KL. Jacobsen EJ. J. Org. Chem.  1995,  60:  4177 
    CrossrefGoogle Scholar
  • For an excellent review on vicinal diamines, see:
  • 10a Lucet D. Le Gall T. Mioskowski C. Angew. Chem. Int. Ed.  1998,  37:  2580 
    CrossrefGoogle Scholar
  • 10b For recent references, see: Coldham I. Copley RCB. Haxell TFN. Howard S. Org. Lett.  2001,  3:  3799 
    CrossrefGoogle Scholar
  • 10c See also: Seo R. Ishizuka T. Abdel-Aziz AA.-M. Kunieda T. Tetrahedron Lett.  2001,  42:  6353 
    CrossrefGoogle Scholar
  • 10d Demay S. Kotschy A. Knochel P. Synthesis  2001,  863 
    CrossrefGoogle Scholar
  • 10e Lee S. Lim CW. Lee JK. Jung O.-S. Lee Y. Tetrahedron: Asymmetry  2000,  11:  4709 
    CrossrefGoogle Scholar
  • 11a López-Rodríguez ML. Viso A. Benhamú B. Rominguera JL. Murcia M. Bioorg. Med. Chem. Lett.  1999,  9:  2339 
    CrossrefGoogle Scholar
  • 11b López-Rodríguez ML. Benhamú B. Ayala D. Rominguera JL. Murcia M. Ramos JA. Viso A. Tetrahedron  2000,  56:  3245 
    CrossrefGoogle Scholar
  • 11c López-Rodríguez ML. Morcillo MJ. Fernández E. Porras E. Orensanz L. Beneytez ME. Manzanares J. Fuentes JA. J. Med. Chem.  2001,  44:  186 
    CrossrefGoogle Scholar
  • 11d López-Rodríguez ML. Morcillo MJ. Fernández E. Rosado ML. Pardo L. Schaper K.-J. J. Med. Chem.  2001,  44:  198 
    CrossrefGoogle Scholar
  • 12a Viso A. Fernández de la Pradilla R. Guerrero-Strachan C. Alonso M. Martínez-Ripoll M. André I. J. Org. Chem.  1997,  62:  2316 
    Google Scholar
  • 12b Viso A. Fernández de la Pradilla R. García A. Alonso M. Guerrero-Strachan C. Fonseca I. Synlett  1999,  1543 
    Google Scholar
  • 12c Viso A. Fernández de la Pradilla R. Recent Res. Devel. Organic Chem.  2000,  4:  327 
    Google Scholar
  • For a review on sulfinimines, see:
  • 13a Davis FA. Zhou P. Chen B.-C. Chem. Soc. Rev.  1998,  27:  13 
    Google Scholar
  • 13b For recent references on sulfinimines, see: Davis FA. Chao B. Rao A. Org. Lett.  2001,  3:  3169 
    Google Scholar
  • 13c See also: Lee A. Ellman JA. Org. Lett.  2001,  3:  3707 
    Google Scholar
  • 13d Kumareswaran R. Hassner A. Tetrahedron: Asymmetry  2001,  12:  2269 
    Google Scholar
  • 13e Wilhelm R. Widdowson DA. Org. Lett.  2001,  3:  3079 
    Google Scholar
  • 13f Surya Prakash GK. Mandal M. Olah GA. Org. Lett.  2001,  3:  2847 
    Google Scholar
  • 13g Asensio A. Bravo P. Crucianelli M. Farina A. Fustero S. García Soler J. Meille SV. Panzeri W. Viani F. Volonterio A. Zanda M. Eur. J. Org. Chem.  2001,  1449 
    Google Scholar
  • 15a The treatment of enantiopure N-sulfinyloxazolidinones with lithium alkoxides results in clean inversion at sulfur to produce enantiopure sulfinate esters. See: Evans DA. Faul MM. Colombo L. Bisaha JJ. Clardy J. Cherry D. J. Am. Chem. Soc.  1992,  114:  5977 
    CrossrefGoogle Scholar
  • 15b

    Synthesis of (+)-(5R,6S)-1-benzyl-5-ethyl-6-hydroxymethylpiperazin-2,3-dione, 2a. From 1a (416 mg, 1.20 mmol) in anhyd CH2Cl2 (6 mL/mmol) at r.t., with diethyl oxalate (0.98 mL, 7.20 mmol, 6 equiv) and 0.5 equiv of a solution of NaOMe in MeOH (0.3 M, 2 mL, 0.60 mmol) a crude product was obtained after standard extractive isolation. Purification by washing thoroughly the crude product with 90% Et2O-hexane and chromatography (5% MeOH-CH2Cl2) of the mother liquor afforded 250 mg (0.95 mmol, 79%) of 2a as a white solid. Data of 2a: mp: 90-92 °C. Rf = 0.25 (12:1 CH2Cl2-MeOH). [α]20 D +166.5 (c 1.19, MeOH). 1H NMR (CD3OD, 400 MHz): δ = 0.75 (t, 3 H, J = 7.5 H), 1.33 (m, 1 H), 1.55 (m, 1 H), 3.52 (m, 1 H), 3.61 (ddd, 1 H, J = 7.6, 5.0, 1.1 Hz), 3.87 (dd, 1 H, J = 11.2, 7.6 Hz), 3.96 (dd, 1 H, J = 11.2, 5.0 Hz), 4.25 (d, 1 H, J = 14.2 Hz), 5.53 (d, 1 H, J = 14.2 Hz), 7.57 (m, 5 H). 13C NMR (DMSO-d6, 50 MHz): δ = 10.4, 28.2, 49.2, 50.6, 58.0, 61.0, 128.5, 129.3 (2 C), 129.6 (2 C), 137.5, 157.4, 157.8. IR(film): 3413, 2928, 1665, 1454, 1117, 1052, 757, 705 cm-1. MS (ES): 297 [M + Cl]+ (100%). Anal. Calcd for C14H18N2O3: C, 64.10; H, 6.92; N, 10.68. Found: C, 63.85; H, 7.04; N, 10.49.
    Crossref
  • 16 Initial attempts performed with LiAlH4 as reducing agent gave the expected piperazines in poor yields, see: Falorni M. Lardicci L. Giacomelli G. Marchetti M. Tetrahedron Lett.  1989,  30:  3551 
    CrossrefGoogle Scholar
  • 18 Dinsmore CJ. Bergman JM. Bogusky MJ. Culberson JC. Hamilton KA. Graham SL. Org. Lett.  2001,  3:  865 
    CrossrefGoogle Scholar
14

The preparation of 1a-c and 1f was carried out following the procedures described in ref. [12b] ; details will be published soon in a full account on this chemistry.

17

Synthesis of (-)-(2S,3R)-1-benzyl-3-ethyl-2-hydroxy-methylpiperazine, 4a. From 2a (188 mg, 0.713 mmol) in
anhyd THF (10 mL/mmol) with 9 equiv of BH3·SMe2 in THF (2 M, 3.21 mL, 6.417 mmol), after refluxing for 7 h, removal of the solvent and sequential treatment with 4 equiv of a 0.4 M HCl (30 min at 100 °C) and 6 equiv of a 0.4 M solution of NaOH (90 min at 0 ºC) a crude product was obtained after standard extractive isolation. Purification by chromatography (0-20% MeOH-Et2O) afforded 123 mg (0.525 mmol, 75%) of 4a as a colorless oil. Data of 4a: Rf = 0.10 (40% MeOH-Et2O). [α]20 D -14.1 (c 0.91, CHCl3). 1H NMR (CDCl3, 300 MHz): δ = 0.92 (t, 3 H, J = 7.3 Hz), 1.48 (sept, 1 H, J = 7.6 Hz), 1.72 (m, 1 H), 2.19 (m, 1 H), 2.29 (dt, 1 H, J = 9.9, 3.0 Hz), 2.70 (m, 1 H), 2.78-2.96 (m, 3 H), 3.29 (d, 1 H, J = 13.3 Hz), 3.65 (dd, 1 H, J = 11.7, 1.6 Hz), 4.02 (d, 1 H, J = 13.3 Hz), 4.05 (dd, 1 H, J = 11.8, 3.2 Hz), 7.26 (m, 5 H). 13C NMR (CDCl3, 50 MHz): δ = 10.3, 25.1, 43.1, 50.5, 58.3, 59.1, 63.3, 127.0, 128.3 (2 C), 128.7 (2 C), 138.4. IR(film): 3306, 3057, 3021, 2958, 1490, 1452, 1027, 739, 699 cm-1. MS (ES): 235 [M + 1]+ (100%).

19

Synthesis of (+)-(5R,6S,S S )-1-benzyl-6-[(t-butyldimethyl-silyloxy)methyl]-5-ethyl-4-(p-tolylsulfinyl)piperazin-2-one, 11. From 10 (315 mg, 0.59 mmol) in DMF (6 mL, 10 mL/mmol) at r.t., with 1.8 equiv of Cs2CO3 (340 mg, 1.04 mmol) at 65 °C (2 h) a crude product was obtained after standard extractive isolation. Purification by chromatography on silica gel (0-30% Et2O-CH2Cl2) afforded 269 mg (0.54 mmol, 92%) of 11 as a white foam. Data of 11: Rf = 0.27 (10% Et2O-CH2Cl2). [α]20 D +61.1 (c 1.10, CHCl3). 1H NMR (CDCl3, 500 MHz): δ = 0.07 (s, 3 H), 0.10 (s, 3 H), 0.54 (t, 3 H, J = 7.5 Hz), 0.90 (s, 9 H), 1.33-1.42 (m, 1 H), 1.75-1.83 (m, 1 H), 2.39 (s, 3 H), 3.08 (d, 1 H, J = 17.7 Hz), 3.26 (ddd, 1 H, J = 8.3, 5.3, 1.5 Hz), 3.66 (dd, 1 H, J = 9.8, 8.5 Hz), 3.71 (dd, 1 H, J = 9.7, 5.3 Hz), 3.75 (ddd, 1 H, J = 10.2, 4.7, 1.5 Hz), 3.80 (d, 1 H, J = 17.7 Hz), 3.84 (d, 1 H, J = 14.3 Hz), 5.33 (d, 1 H, J = 14.3 Hz), 7.24-7.33 (m, 7 H), 7.47 (d, 2 H, J = 8.1 Hz). 13C NMR (CDCl3, 50 MHz): δ = -5.3, -5.2, 10.3, 18.1, 21.3, 22.5, 25.8 (3 C), 39.7, 48.6, 57.8, 59.1, 62.4, 125.6 (2 C), 128.0, 128.8 (2 C), 128.9 (2 C), 129.8 (2 C), 136.6, 139.3, 141.8, 165.5. IR(film): 2963, 2855, 1732, 1646, 1435, 1260, 1090, 1018, 799 cm-1. MS (ES): 501 [M + 1]+ (100%), 502 [M + 2]+, 503 [M + 3]+, 523 [M + Na]+.
Synthesis of (+)-(5R,6S)-1-benzyl-6-(t-butyldimethylsilyl-oxymethyl)-5-ethyl-5,6-dihydro-1H-pyrazin-2-one, 12. From a cold (0 °C) suspension of 4 equiv of NaH in anhyd THF (5 mL/mmol of NaH), with a solution of 11 (72 mg, 0.144 mmol) in THF (5 mL/mmol) after stirring at r.t. (1 h) and at reflux (1 h), a crude product was obtained after standard extractive isolation. Purification by chromato-graphy on silica gel (30-80% Et2O-hexane) afforded 43 mg (0.119 mmol, 83%) of 12 as a colorless oil. Data of 12: Rf = 0.38 (80% Et2O-hexane). [α]20 D +188.3 (c 1.23, CHCl3). 1H NMR (CDCl3, 500 MHz): δ = 0.05 (s, 6 H), 0.54 (t, 3 H, J = 7.4 Hz), 0.86 (s, 9 H), 0.86-0.98 (m, 1 H), 1.40-1.49 (m, 1 H), 3.27 (ap t, 1 H, J = 6.5 Hz), 3.55 (dd, 1 H, J = 10.2, 6.9 Hz), 3.63 (dd, 1 H, J = 10.2, 5.8 Hz), 3.78 (dd, 1 H, J = 7.7, 5.5 Hz), 3.92 (d, 1 H, J = 14.3 Hz), 5.34 (d, 1 H, J = 14.3 Hz), 7.26-7.34 (m, 5 H), 7.70 (d, 1 H, J = 1.5 Hz). 13C NMR (CDCl3, 50 MHz): δ = -5.6, -5.5, 10.2, 18.1, 25.8 (4 C), 48.4, 55.2, 59.4, 63.0, 128.1, 128.8 (2 C), 129.1 (2 C), 136.1, 155.1 (2 C). IR(film): 3400, 3030, 2929, 2857, 1674, 1632, 1454, 1361, 1258, 1101, 908, 838, 804, 779, 704 cm-1. MS (ES): 361 [M + 1]+ (100%), 743 [2 M + Na]+.